Roivant Sciences Ltd（ROIV）股票分析ROIVRoivant Sciences Ltd

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Roivant Sciences Ltd (ROIV) is a good buy right now due to its current price of $36.49, which is below the average analyst price target of $46, suggesting a potential upside of 26%. Additionally, the stock has shown a strong year-to-date change of +66.39% and a recent 5-day change of +8.83%, indicating positive momentum. However, the main risk is its negative net income, which was -265.89 million USD in Q3 2026, highlighting ongoing financial challenges that investors should consider.